An innovative venture firm with an early-stage fund and a global ecosystem of support for efficiently launching cutting-edge companies developing tools and technologies in the Cell and Gene Therapy space.
Advanced therapies revolutionize life sciences, offering immense therapeutic potential and commercial opportunities. However, a crucial deficiency in tools and technology obstructs global accessibility and affordability. This obstacle results in patient mortality on waitlists due to challenges in scaling and the incapacity of current technologies to meet market demand effectively.
ABV Fund boasts a specialized AT talent team—top-tier sourcers, a world-class advisory board, and a diverse investment committee. We invest $250k-$500k, prioritizing equity-focused instruments like common stock, convertibles, and SAFE Notes.
Our unique accelerator program empowers our portfolio startups to lead in state-of-the-art AT technologies and tools. Selected portfolio companies contribute to the program cost, usually $50k, from the investment they receive.
Startups at a very early stage are offered a place in a pre-accelerator course or bootcamp. Here, they refine their ideas and skills, gaining valuable knowledge and strategies to optimize fundraising success.
Founding Partner,
Managing Director
Paris, France
Founding Partner,
Sourcing Team
Vancouver, Canada
Founding Partner,
Investment Team
Vancouver, Canada
Founding Partner,
Portfolio Team
Amsterdam, Netherland
Strategic Advisory Board,
Product Scalability
Cambridge, USA
Strategic Advisory Board,
Commercial Readiness
Boston, USA
Strategic Advisory Board,
Analytical Technologies
Lyon, France
Investment Committee, Advisor and Investor
Frederick, USA
Investment Committee,
Entrepreneur and Investor
London, UK
Investment Committee, Advisor and Investor
Tokyo, Japan
120 Lonsdale Avenue, North Vancouver, British Columbia V7L 1B1, Canada
Monday - Friday: 8:00am - 5:00pm
Saturday - Sunday: Closed
Nous utilisons des cookies pour analyser le trafic du site Web et optimiser votre expérience du site. Lorsque vous acceptez notre utilisation des cookies, vos données seront agrégées avec toutes les autres données utilisateur.